GlaxoSmithKline Boosts Stake in Theravance

NEW YORK ( TheStreet) -- Drug company GlaxoSmithKline ( GSK) announced Monday that it is acquiring 10 million shares of biopharmaceutical firm Theravance ( THRX) for about $212.9 million.

GlaxoSmithKline currently owns 18.3% of Theravance and the acquisition would increase its ownership to 26.8%.

-- Written by Alexandra Zendrian

>To contact the writer of this article, click here: Alexandra Zendrian

>To submit a news tip, send an email to: tips@thestreet.com.

>To follow the writer on Twitter, go to Alexandra Zendrian.

If you liked this article you might like

Theravance (THRX) Highlighted As Weak On High Volume

Theravance (THRX) Highlighted As Weak On High Volume

Theravance (THRX) Flagged As Strong On High Volume

Theravance (THRX) Flagged As Strong On High Volume

3 Sell-Rated Dividend Stocks: VER, BRS, THRX

3 Sell-Rated Dividend Stocks: VER, BRS, THRX

The 10 Highest Dividend Health Care Stocks Are Not All Buys

The 10 Highest Dividend Health Care Stocks Are Not All Buys

5 Hated Stocks You Should Love This Earnings Season

5 Hated Stocks You Should Love This Earnings Season